NexImmune is a rapidly growing leader in the emerging field of antigen-directed immunotherapies. We are developing a novel technology that uses natural biology to orchestrate a targeted cell-mediated immune response across a broad range of diseases. We can customize our technology to “intensify” a targeted immune response to treat cancer or infectious disease. Conversely, we can also customize it to “dampen” an overactive immune response to treat autoimmune disorders.
Ticker:
NEXI
Exchange:
Nasdaq
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
2013
Main Therapeutic Focus:
Immunology
Lead Product in Development:
NEXI - 001
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
3+
Speaker
